Old Silver VC is an evergreen family-associated fund that makes early stage investments in Biotech, Digital Health, AI, and Material Sciences. We believe that the world’s greatest problems can be solved with innovative science and technology solutions. We seek and support early-stage founders with a vision that can scale from science fiction to new reality.
Michael is the Founding Partner at Old Silver VC, the Head of Search and Evaluation at Pear Therapeutics and a World Economic Forum Global Shaper.
Vice President of Business Development at a Cambridge-based cell state start up in stealth mode.
Andrew Emmons, MBA
Focuses on early-stage investments in the technology, SaaS, and healthcare industries.
Well versed in corporate development and strategic & operational excellence focusing on biotechnology and healthcare.
Corporate strategy & development at Valo Health, head of partnerships & licensing at 2 Minute Medicine, co-founder and board director at Nucleate Bio. Fund advisor specializing in translational biotechnology, AI drug discovery and platform strategy.
PhD Candidate at Stanford University researching biomaterial-based immunomodulation strategies for tissue engineering
David Paik, PhD
Instructor at Stanford Cardiovascular Institute and Stanford University School of Medicine. Current focus of research is in advancing cardiovascular precision medicine using single-cell omics and patient-specific induced pluripotent stem cell models.
Hannah Bolland, PhD
Postdoctoral researcher at Oxford University working in the field of tumour hypoxia, reactive oxygen species and development of novel fluorescent and responsive MRI probes to measure hypoxia.
Undergraduate at Princeton University researching breast cancer bone metastasis and application of scRNA-seq technology
Dartmouth Tuck MBA candidate with experience in biopharma R&D, project management, corporate and business development, and venture capital.
Lara Maggs, MBE
PhD candidate in genetics and molecular biology studying translation synthesis, a DNA damage response pathway in which specialized polymerases traverse blocking DNA lesions. Bioethicist focused on the ethical implications of germline gene editing.
Michael Trinh, PhD
MD-PhD candidate at the University of Texas Southwestern Medical Center studying cholesterol metabolism
Sunil Yadav, PhD
Postdoctoral researcher at Stanford University School of Medicine researching targeted therapies for genetic cardiomyopathies.
Tiffany Ma, MTM
PhD candidate at the University of Oxford researching strategies to target therapy-resistant tumours in solid cancers.
Senior software engineer at Microsoft whose expertise spans multiple verticals of the software engineering domains and a number of programming languages including C, C++, C# and Python.
Alicia Chong Rodriguez, MS, MSc
Femtech Catalyst, Founder & CEO at Bloomer Tech: Tailoring cardiovascular care for women via an augmented garment platform and novel digital biomarkers.
Debbie Lin, PhD
Healthtech investor is currently excited about digital health, med devices, new materials, AI and drug discovery tools.
David Mou, MBA, MD
Chief Medical Officer at Cerebral & Co-founder / former CMO of Valera Health, a venture-backed digital healthcare company.
Emilia Javorsky, MD, MPH
Physician-Scientist and former Harvard Medical School researcher focused on the development and translation of medical technologies.
Everett Crosland, MS, JD
Life sciences executive, with a proven track record commercializing and scaling complex drugs, drug-device combos, and digital therapeutics.
Co-founder of ThoughtMetric Inc- a next-generation analytics platform designed to help Mid-Market and SMB eCommerce stores better understand their customers.
Jordan Haviland, MBA
CEO of Brattle Point, LLC, where he focuses on acquiring growing technology and service businesses in scientific and industrial markets.
Livio Valenti, MPP
Sustainability entrepreneur and co-founder of Vaxess Technologies, a biotechnology company reimagining vaccine delivery.
Liz Kwo, MD, MBA, MPH
Deputy Chief Clinical Officer at Anthem & Co-Founder / former CEO of InfiniteMD.
Louis Kang, PhD
Managing Director at AccelR8, Co-Founder at MitoLab, Venture Partner at Korea Technology Bank (KTB) VC
M.D. candidate at the Perelman School of Medicine passionate about innovation in biotech, digital health, and health equity.
Head of Bio & Deep Tech at BoxOne Ventures, Venture Partner at Entrepreneur First, and active angel investor. A neuroscientist by training, turned entrepreneur, and active investor. Appointed as a Strategic Advisor to LifeOmic, and as an External Advisor to AstraZeneca.
Founding Partner at First Star Ventures, an early-stage venture fund focuses on cutting edge data technologies.
Partner at Arkitekt Ventures
Rebecca Maynard, LLM, JD
Compliance & Privacy Specialist at Boston Children's Hospital
Head of CX at NLP startup Forethought.ai, winner of TechCrunch Disrupt and funded by NEA, Village Global, K9 Ventures, etc.
Ryan Coles, MS, PHD
Assistant Professor of Entrepreneurial Management at UConn's School of Business, and the Chief Science Officer at Human Wealth.
Sean Cheng, MP, PHD
Early stage investor in health tech companies and is currently excited about digital therapeutics, remote patient care, novel devices, and disruptive enablers.
Sophie Bai, MBA
Founder and CEO of a biotech company using novel transdermal drug delivery technologies to get large molecules into the skin.
Zack Gow, ME, MS
Data scientist, machine learning engineer, and entrepreneur.
Freddie Martignetti, MBA
Investor at Highland Capital Partners, a global leader in early stage consumer and enterprise technology investments.
Robert Langer, Sc. D
Dr. Langer is one of 10 Institute professors at MIT (MITs highest honor). He is an expert in the fields of tissue engineering and drug delivery and has founded over 40 startup companies. He is the most cited engineer in history.
The world's only multi-lead ECG heart health wearable bra.Visit The Site
Developing technology to drive the mining industry into a new place of increased output, stronger economics, and long term sustainability. Visit The Site
Replacing chemicals banned by the FDA with 100% sustainable and safe ingredients from recycled marine biomaterials (branded OceanSafe™).Visit The Site
Building the metaverse for 'new work'. Forward-looking companies move in to virtual offices in Sophya to build culture and achieve business results.Visit The Site
Developing a platform to mass produce insects as the world’s most sustainable protein. Visit The Site
Improving human health by making it far easier to design advanced, next-generation antibody therapeutics.Visit The Site
Cultivated meat start-up pioneering a new approach to producing meat by growing real meat cells without the animal, enabling a sustainable supply chain as well as a more resilient food ecosystem.Visit The Site
Extremely robust, end-to-end plant genetic engineering platform–from bioinformatics-based trait discovery to regenerative protoplast testing to greenhouse/field testing.Visit The Site
Making a major shift in how immunology therapies are discovered and developed by integrating machine learning together with protein engineering, structural biology and translational immunology throughout the entire drug discovery and development process.Visit The Site
The pioneer of a new, accessible healthcare system that connects the millions of uninsured and underserved Americans to superior physicians at half of the traditional priceVisit The Site
An automated lab platform for life sciences transforming healthcare, biopharma, and R&DVisit The Site
Prior Investments or Early Shareholder Positions
A full-service pharmacy that delivers prescriptions to your door for free, seven days a week. Visit The Site
Using machine learning to make customizable voice skins for the gaming industry.Visit The Site
Creating a new frontier in visual and neurological care that extracts the full value of virtual reality technology. Visit The Site
An AI powered search engine to optimize drug discovery for pharmaceutical companies.Visit The Site
A global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering with mental health disorders.Visit The Site
Creating all-natural protective layers to slow down the spoiling process of fruit, vegetables, meat, and seafood. Visit The Site
An American biotechnology company based in Cambridge, Massachusetts that focus on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA.Visit The Site
A clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases.Visit The Site
A biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases.Visit The Site
Momenta Pharmaceuticals is a biotechnology company with a validated, innovative scientific platform.Visit The Site
A biopharmaceutical company committed to advancing the treatment of eye diseases. Visit The Site
Lyndra Therapeutics is a developer of a novel therapeutic platform designed to sustain extended drug release in oral dosage form.Visit The Site
Creating immune-protected, engineered human cells that restore normal physiology in a wide range of diseases without generating fibrosis or immune rejection, liberating patients from challenges associated with serious chronic diseasesVisit The Site
Developing innovative solutions that act as a gateway to the proteome.Visit The Site
A clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions.Visit The Site
Cruelty-free, paraben-free & silicone-free haircare products.Visit The Site
Vida Ventures is a bio-coastal life sciences company transforming biomedical innovations into therapies. Visit The Site
A Boston based seed fund focused on consumer digital, sports & marketplaces, and AI, data & security. Visit The Site